Long-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation. We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in relapsed/refractory AML. The main endpoints were: the rate of complete remissions (CR) and the proportion of patients capable of undergoing a stem cell transplant. Fourty-two patients were enrolled. The overall CR rate was 76% and no induction deaths were reported. In 56% of patients, a transplant procedure could be performed. The treatment schedule proved feasible and well tolerated, providing a high CR rate and a useful bridge to transplant.
Ara-C, idarubicine and Gentuzumab ozogamicin (AIM) as salvage treatment in advanced acute myeloid leukemia patients / Saveria, Capria; Silvia Maria, Trisolini; Clara, Minotti; Stefanizzi, Caterina; Luisa, Cardarelli; Claudio, Cartoni; Daniela, Diverio; Maria Stefania De, Propris; Marco, Mancini; Micozzi, Alessandra; Foa, Roberto; Meloni, Giovanna. - In: MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES. - ISSN 2035-3006. - 4:1(2012), p. 2012072. [10.4084/mjhid.2012.072]
Ara-C, idarubicine and Gentuzumab ozogamicin (AIM) as salvage treatment in advanced acute myeloid leukemia patients
STEFANIZZI, CATERINA;MICOZZI, Alessandra;FOA, Roberto;MELONI, Giovanna
2012
Abstract
Long-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation. We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in relapsed/refractory AML. The main endpoints were: the rate of complete remissions (CR) and the proportion of patients capable of undergoing a stem cell transplant. Fourty-two patients were enrolled. The overall CR rate was 76% and no induction deaths were reported. In 56% of patients, a transplant procedure could be performed. The treatment schedule proved feasible and well tolerated, providing a high CR rate and a useful bridge to transplant.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
